An oncology-focused biotechnology company developing and commercializing targeted therapies for cancer. Its primary asset has been tivozanib, marketed as FOTIVDA, a treatment for relapsed or refractory renal cell carcinoma, with additional clinical programs historically aimed at other tumor types. I...
1 member of Congress has disclosed 2 trades in AVEO Pharmaceuticals Inc (AVEO), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-06-27 | JAMES B. RENACCI | buy | $1K – $15K |
| 2017-04-25 | JAMES B. RENACCI | buy | $1K – $15K |